NeuroImage: Clinical
September 19, 2022
Josua Zimmermann, Nicole Friedli, Francesco Bavato et al.
14 citations
3,4–Methylenedioxymethamphetamine (MDMA, “Ecstasy”) is a serotonin- and noradrenaline-releasing substance, currently among the most widely used illicit substances worldwide. In animal studies, repeated exposure to MDMA has been associated with dendritic but also axonal degeneration in the brain. However, translation of the axonal findings, specifically, to humans has been repeatedly questioned...
Psychoanalytic Dialogues
September 3, 2022
Megan Rundel
ABSTRACT As the use of psychedelic agents become a part of mental health treatment, psychoanalysts have the challenge of theorizing how they affect the psyche and the relational field, as well as how they might become part of an analytic process. In this paper, I explore three aspects of psychedelic experience and some ways we might start to understand them in analytic terms. I discuss states...
Annales de Toxicologie Analytique
September 1, 2022
M. Augsburger, J. Déglon, Christèle Widmer et al.
Aim: Swiss drug policy aims to reduce recreational drug consumption and its negative consequences. The strategy is based on a four pillars concept: prevention, therapy, harm reduction and repression. Among harm reduction programs drug checking (DC) facilities have emerged, allowing drug users to check the presence of adulterants or other non-expected substances, and to gain information...
Addictive Behaviors
September 1, 2022
Kevin H. Yang, Benjamin H Han, Joseph J Palamar
30 citations
There is renewed interest in the clinical application of hallucinogenic substances to treat a range of psychiatric conditions. However, there is mixed evidence regarding how use of such substances outside of medical settings relates to psychological distress, depression, and suicidality. We examined data from a US representative sample of noninstitutionalized adults from the 2015-2020 National...
Central European journal of public health
September 1, 2022
Pavla Chomynová, Rita Kočárová, Filip Kňažek et al.
2 citations
Different psychoactive substances are widely used in today's society. So far limited data are available on the use of psychedelics in the general population. The main aim of this study is to estimate the numbers of users of substances with psychedelic properties (classical psychedelics, cannabis, ecstasy, and ketamine) in the Czech Republic. Data from two samples enrolled in representative...
Alcoholism and Drug Addiction
August 31, 2022
Katarzyna Karaś, Katarzyna Groblińska, Krzysztof Szczygieł et al.
Research on the use of psychoactive substances in mental disorder treatment has become increasingly important over the last 50 years. Numerous publications suggest their effectiveness in the treatment of many diseases, including depression and anxiety disorders, PTSD, psychoactive substance dependence, ADHD and Tourette’s Syndrome. Particularly noteworthy is the use of psychedelics such as...
Cygne Noir
August 19, 2022
Simon Lévesque
1 citation
Dans cet entretien réalisé par Simon Levesque pour le compte du Cygne noir, Ansgar Rougemont-Bücking discute de sa pratique psychiatrique et psychothérapeutique, qui passe par l’administration de substances psychédéliques (kétamine, MDMA, LSD et psilocybine) à ses patient·e·s. Cette pratique médicale prend place dans le cadre de son cabinet privé, à Vevey en Suisse. Le docteur Rougemont-Bücking...
Expert Opinion on Investigational Drugs
August 17, 2022
Bartłomiej Pochwat, A. Krupa, M. Siwek et al.
ABSTRACT Introduction Pharmacotherapy of depression is characterized by the delayed onset of action, chronic treatment requirements, and insufficient effectiveness. Ketamine, with its rapid action and long-lasting effects, represents a breakthrough in the modern pharmacotherapy of depression. Areas covered The current review summarizes the latest findings on the mechanism of the antidepressant...
Archives of Clinical Neuropsychology
August 17, 2022
Brian Peacock
3 citations
Abstract Objective: Psychedelic-assisted therapies are emerging as safe and effective treatments for some psychological conditions including depression, anxiety, posttraumatic stress disorder, and substance use disorders. As ketamine therapy is already available in general medicine and 3,4 Methylenedioxymethamphetamine (MDMA) and psilocybin are in late-stage clinical trials, neuropsychologists...
Current Addiction Reports
August 15, 2022
Bradford Martins, Will Rutland, Joao P De Aquino et al.
Purpose of review: This review summarizes recent clinical trial research on pharmacological treatments for substance use disorders, with a specific focus on agents with potential abuse liability. Recent findings: Pharmacological treatments for substance use disorders may include gabapentinoids, baclofen, modafinil, ketamine, cannabinoids, gamma-hydroxybutyrate, and psychedelics. Gabapentinoids...